SII to start production of Novavax’s Covid Vaccine

The COVID-19 vaccine created by US biotechnology organization Novavax protein-based Covid-19 antibody, NVX-CoV2373 will before long be accessible in India under the brand name Covovax. The vaccine will be privately made and appropriated by the Serum Institute of India (SII) as Covovax. This will be notwithstanding the all-around supported Covishield, Covaxin, and Sputnik V.

Prior to March, SII CEO Adar Poonawalla had said that clinical preliminaries of the antibody ‘Covovax’ have started in India, and the organization desires to dispatch it by September this year.

“Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and SerumInstIndia. It has been tested against African and UK variants of COVID19 and has overall efficacy of 89%. Hope to launch by September 2021,” he had tweeted.

On Monday, SII said its COVID-19 vaccine competitor was exceptionally viable with 90.4 percent adequacy generally speaking and furthermore showed high viability against dominatingly flowing variations.

“After Novavax gets approvals abroad with efficacy trials, then we can look at maybe launching it in India. Having said that, I still want to complete my trials in India for Covovax to be absolutely sure that this product we made is identical to Novavax, and we want to adhere to those standards before we launch the product in India, so it’s going to take two-three months. But the good news is that if we can start stockpiling enough quantities, it won’t matter because, in three or four months, we can then give those doses to India, and other parts of the world. The key issue is that we are going to establish that the quality of the product that we are making and stockpiling here is identical to standard quality compared to Novavax, and that’s going to take a couple of months,” SII chief executive officer Adar Poonawalla said.

“Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection,” Novavax president and CEO Stanley C Erck said.